JPWO2020072605A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072605A5 JPWO2020072605A5 JP2021517993A JP2021517993A JPWO2020072605A5 JP WO2020072605 A5 JPWO2020072605 A5 JP WO2020072605A5 JP 2021517993 A JP2021517993 A JP 2021517993A JP 2021517993 A JP2021517993 A JP 2021517993A JP WO2020072605 A5 JPWO2020072605 A5 JP WO2020072605A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkylene
- linear
- compound
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 88
- 239000000203 mixture Substances 0.000 claims description 55
- 125000002947 alkylene group Chemical group 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 19
- 108020005004 Guide RNA Proteins 0.000 claims description 17
- 150000002632 lipids Chemical class 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 238000010362 genome editing Methods 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 101710163270 Nuclease Proteins 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 230000004568 DNA-binding Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000007018 DNA scission Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024074775A JP2024102224A (ja) | 2018-10-02 | 2024-05-02 | イオン化可能なアミン脂質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740274P | 2018-10-02 | 2018-10-02 | |
| US62/740,274 | 2018-10-02 | ||
| PCT/US2019/054240 WO2020072605A1 (en) | 2018-10-02 | 2019-10-02 | Ionizable amine lipids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024074775A Division JP2024102224A (ja) | 2018-10-02 | 2024-05-02 | イオン化可能なアミン脂質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501412A JP2022501412A (ja) | 2022-01-06 |
| JPWO2020072605A5 true JPWO2020072605A5 (zh) | 2022-10-07 |
| JP7485659B2 JP7485659B2 (ja) | 2024-05-16 |
Family
ID=68425250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517993A Active JP7485659B2 (ja) | 2018-10-02 | 2019-10-02 | イオン化可能なアミン脂質 |
| JP2024074775A Pending JP2024102224A (ja) | 2018-10-02 | 2024-05-02 | イオン化可能なアミン脂質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024074775A Pending JP2024102224A (ja) | 2018-10-02 | 2024-05-02 | イオン化可能なアミン脂質 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220009878A1 (zh) |
| EP (1) | EP3860972A1 (zh) |
| JP (2) | JP7485659B2 (zh) |
| KR (1) | KR20210093871A (zh) |
| CN (1) | CN113039174B (zh) |
| AU (1) | AU2019351917A1 (zh) |
| BR (1) | BR112021006270A2 (zh) |
| CA (1) | CA3114032A1 (zh) |
| CO (1) | CO2021005774A2 (zh) |
| EA (1) | EA202190916A1 (zh) |
| IL (1) | IL281948A (zh) |
| MX (1) | MX2021003455A (zh) |
| PH (1) | PH12021550701A1 (zh) |
| SG (1) | SG11202102921WA (zh) |
| TW (1) | TW202028170A (zh) |
| UA (1) | UA128190C2 (zh) |
| WO (1) | WO2020072605A1 (zh) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022013254A (es) | 2020-04-22 | 2023-01-24 | BioNTech SE | Vacuna contra el coronavirus. |
| KR20230017783A (ko) | 2020-04-28 | 2023-02-06 | 인텔리아 테라퓨틱스, 인크. | 시험관내 세포 전달 방법 |
| CA3198309A1 (en) * | 2020-11-16 | 2022-05-19 | Heinrich Haas | Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same |
| CA3198742A1 (en) * | 2020-11-16 | 2022-05-19 | Steffen Panzner | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| US20240041785A1 (en) * | 2020-11-16 | 2024-02-08 | BioNTech SE | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines |
| WO2022218503A1 (en) * | 2021-04-12 | 2022-10-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| TW202237845A (zh) | 2020-12-11 | 2022-10-01 | 美商英特利亞醫療公司 | 用於涉及去胺作用之基因體編輯之多核苷酸、組合物及方法 |
| CN116782913A (zh) * | 2020-12-21 | 2023-09-19 | 比姆医疗股份有限公司 | 包括缩醛的纳米材料 |
| EP4262818A1 (en) * | 2020-12-21 | 2023-10-25 | Beam Therapeutics Inc. | Nanomaterials comprising carbonates |
| AU2021410666A1 (en) * | 2020-12-21 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterials comprising ester-linked acetals |
| US20220249694A1 (en) * | 2021-01-20 | 2022-08-11 | Beam Therapeutics Inc. | Nanomaterials comprising a biodegradable feature |
| US12059477B2 (en) | 2021-01-20 | 2024-08-13 | Beam Therapeutics Inc. | Nanomaterials |
| CN112961065B (zh) * | 2021-02-05 | 2023-03-14 | 嘉晨西海(杭州)生物技术有限公司 | 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用 |
| CA3206923A1 (en) * | 2021-02-05 | 2022-08-11 | Zihao Wang | Ionizable lipid molecule, preparation method therefor, and application thereof in preparation of lipid nanoparticle |
| CN115515926B (zh) * | 2021-04-08 | 2023-10-20 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| US20240300977A1 (en) | 2021-04-17 | 2024-09-12 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
| TW202308596A (zh) | 2021-04-17 | 2023-03-01 | 美商英特利亞醫療公司 | 脂質奈米顆粒組合物 |
| WO2022251665A1 (en) * | 2021-05-28 | 2022-12-01 | Renagade Therapeutics Management Inc. | Lipid nanoparticles and methods of use thereof |
| WO2022261292A1 (en) | 2021-06-10 | 2022-12-15 | Intellia Therapeutics, Inc. | Modified guide rnas comprising an internal linker for gene editing |
| EP4359531A1 (en) * | 2021-06-22 | 2024-05-01 | Intellia Therapeutics, Inc. | Methods for in vivo editing of a liver gene |
| WO2023044333A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
| CA3231523A1 (en) * | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| KR20240090727A (ko) | 2021-10-22 | 2024-06-21 | 세일 바이오메디슨스, 인크. | Mrna 백신 조성물 |
| TW202325848A (zh) | 2021-11-03 | 2023-07-01 | 美商英特利亞醫療公司 | 用於基因體編輯之多核苷酸、組合物及方法 |
| WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
| WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
| CN114874104A (zh) * | 2022-04-29 | 2022-08-09 | 湖北英纳氏生物科技有限公司 | 阳离子脂质体sm-102及其类似物的制备方法 |
| WO2023222081A1 (zh) * | 2022-05-19 | 2023-11-23 | 仁景(苏州)生物科技有限公司 | 长链烷基酯胺类脂质化合物及其制备方法和在核酸递送方面的应用 |
| TW202408595A (zh) | 2022-06-16 | 2024-03-01 | 美商英特利亞醫療公司 | 用於對細胞進行遺傳修飾之方法及組合物 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024078614A1 (zh) * | 2022-10-13 | 2024-04-18 | 深圳深信生物科技有限公司 | 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒 |
| WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
| WO2024117978A1 (en) * | 2022-11-30 | 2024-06-06 | Agency For Science, Technology And Research (A*Star) | Methods of synthesising ionisable lipids |
| WO2024138189A2 (en) | 2022-12-22 | 2024-06-27 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| WO2024138115A1 (en) | 2022-12-23 | 2024-06-27 | Intellia Theraperutics, Inc. | Systems and methods for genomic editing |
| WO2024159172A1 (en) | 2023-01-27 | 2024-08-02 | Senda Biosciences, Inc. | A modified lipid composition and uses thereof |
| CN118255678A (zh) * | 2024-03-28 | 2024-06-28 | 荣灿生物医药技术(上海)有限公司 | 一种可电离脂质化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9319398A (en) | 1997-09-19 | 1999-04-05 | Sequitur, Inc. | Sense mrna therapy |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| US20100055169A1 (en) * | 2008-04-16 | 2010-03-04 | Abbott Laboratories | Cationic lipids and uses thereof |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| WO2015095340A1 (en) * | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| SI3350157T1 (sl) | 2015-09-17 | 2022-04-29 | Modernatx, Inc. | Sestave za doziranje terapevtskih sredstev v celice |
| WO2017075531A1 (en) | 2015-10-28 | 2017-05-04 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP4186888A1 (en) * | 2017-03-15 | 2023-05-31 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
-
2019
- 2019-10-02 EA EA202190916A patent/EA202190916A1/ru unknown
- 2019-10-02 BR BR112021006270A patent/BR112021006270A2/pt unknown
- 2019-10-02 JP JP2021517993A patent/JP7485659B2/ja active Active
- 2019-10-02 EP EP19797405.8A patent/EP3860972A1/en active Pending
- 2019-10-02 KR KR1020217013174A patent/KR20210093871A/ko active Search and Examination
- 2019-10-02 AU AU2019351917A patent/AU2019351917A1/en active Pending
- 2019-10-02 US US17/282,157 patent/US20220009878A1/en active Pending
- 2019-10-02 UA UAA202102294A patent/UA128190C2/uk unknown
- 2019-10-02 MX MX2021003455A patent/MX2021003455A/es unknown
- 2019-10-02 CN CN201980071117.XA patent/CN113039174B/zh active Active
- 2019-10-02 SG SG11202102921WA patent/SG11202102921WA/en unknown
- 2019-10-02 CA CA3114032A patent/CA3114032A1/en active Pending
- 2019-10-02 WO PCT/US2019/054240 patent/WO2020072605A1/en active Application Filing
- 2019-10-02 TW TW108135763A patent/TW202028170A/zh unknown
-
2021
- 2021-03-28 PH PH12021550701A patent/PH12021550701A1/en unknown
- 2021-03-31 IL IL281948A patent/IL281948A/en unknown
- 2021-04-30 CO CONC2021/0005774A patent/CO2021005774A2/es unknown
-
2024
- 2024-05-02 JP JP2024074775A patent/JP2024102224A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020072605A5 (zh) | ||
| US11911475B2 (en) | Low molecular weight cationic lipids for oligonucleotide delivery | |
| JPWO2020219876A5 (zh) | ||
| US9604908B2 (en) | Diether based biodegradable cationic lipids for siRNA delivery | |
| JP2021169466A (ja) | テロメラーゼ阻害のための改変オリゴヌクレオチド | |
| CN111406108A (zh) | 制剂 | |
| DE69331524T2 (de) | Verfahren zum spezifischen schneiden von rna-strängen | |
| JP2020536125A5 (zh) | ||
| CA2339834A1 (en) | Water soluble prodrugs of hindered alcohols or phenols | |
| US4507287A (en) | Preparation and method for the treatment of acne | |
| EP1161946A2 (en) | Soluble analogs of probucol | |
| Dedon et al. | Influence of thiol structure on neocarzinostatin activation and expression of DNA damage | |
| JPWO2020118041A5 (zh) | ||
| KR20220164547A (ko) | 효율적인 핵산 전달을 위한 운반체 | |
| US20190119198A1 (en) | Biodegradable amino-ester nanomaterials for nucleic acid delivery | |
| EP2976351B1 (en) | Lipohillic oligonucleotide analogs | |
| EP3777891A1 (en) | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | |
| JPS6210209B2 (zh) | ||
| EP1019417B1 (de) | Phospholipidanaloge verbindungen | |
| JP2021522787A (ja) | 遺伝子治療の方法 | |
| FR2547500A1 (fr) | Preparation pharmaceutique pour ulcere du tube digestif | |
| US20130072543A1 (en) | Compounds and Compositions for Nucleic Acid Formulation and Delivery | |
| Holland et al. | Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance | |
| JPWO2020198697A5 (zh) | ||
| EP3490549A1 (en) | Dermatological formulations of 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate |